ERBB2 and breast cancer: Similarly, the results of the TULIP trial, comparing trastuzumab duocarmazine versus physician’s treatment of choice in pretreated HER2-positive metastatic BC, suggest that this ADC may be a novel therapeutic modality for such patients [28].